CA2887055C - A bordetella pertussis strain encoding a hybrid fha protein for increased immunogenicity and lacking a native fha protein - Google Patents

A bordetella pertussis strain encoding a hybrid fha protein for increased immunogenicity and lacking a native fha protein Download PDF

Info

Publication number
CA2887055C
CA2887055C CA2887055A CA2887055A CA2887055C CA 2887055 C CA2887055 C CA 2887055C CA 2887055 A CA2887055 A CA 2887055A CA 2887055 A CA2887055 A CA 2887055A CA 2887055 C CA2887055 C CA 2887055C
Authority
CA
Canada
Prior art keywords
gene
strain
protein
fha
bordetella pertussis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2887055A
Other languages
English (en)
French (fr)
Other versions
CA2887055A1 (en
Inventor
Camille Locht
Nathalie Mielcarek
Hana KAMMOUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Lille filed Critical Institut Pasteur de Lille
Publication of CA2887055A1 publication Critical patent/CA2887055A1/en
Application granted granted Critical
Publication of CA2887055C publication Critical patent/CA2887055C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2887055A 2012-10-17 2013-10-17 A bordetella pertussis strain encoding a hybrid fha protein for increased immunogenicity and lacking a native fha protein Active CA2887055C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306279.6 2012-10-17
EP12306279.6A EP2722338A1 (en) 2012-10-17 2012-10-17 Novel recombinant Bordetella strains
PCT/EP2013/071724 WO2014060514A1 (en) 2012-10-17 2013-10-17 Novel recombinant bordetella strains

Publications (2)

Publication Number Publication Date
CA2887055A1 CA2887055A1 (en) 2014-04-24
CA2887055C true CA2887055C (en) 2023-03-21

Family

ID=47073385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2887055A Active CA2887055C (en) 2012-10-17 2013-10-17 A bordetella pertussis strain encoding a hybrid fha protein for increased immunogenicity and lacking a native fha protein

Country Status (10)

Country Link
US (1) US9528086B2 (https=)
EP (3) EP2722338A1 (https=)
JP (3) JP6473086B2 (https=)
CN (2) CN110923181A (https=)
AU (1) AU2013333928B2 (https=)
CA (1) CA2887055C (https=)
DK (2) DK3459966T3 (https=)
ES (2) ES2771675T3 (https=)
SG (2) SG10201706392YA (https=)
WO (1) WO2014060514A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119804B2 (en) 2006-03-10 2015-09-01 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
SG175803A1 (en) 2009-04-28 2011-12-29 Pasteur Institut Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
DK2773371T3 (da) 2011-11-02 2020-03-09 Nat Univ Singapore Virkning af en svækket bordetella-stamme mod allergisk sygdom
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
KR101672719B1 (ko) * 2014-07-22 2016-11-04 전남대학교산학협력단 바이러스 중화항원 단백질 발현을 위한 보르데텔라 백일해 균주 및 이를 이용한 면역원성 조성물
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
EP4541809A3 (en) 2016-03-29 2025-06-25 Institut Pasteur de Lille Mutant bordetella strains and methods of use
SG11202003333WA (en) 2017-10-18 2020-05-28 Pasteur Institut Bordetella strains expressing serotype 3 fimbriae
US20220054616A1 (en) * 2019-01-04 2022-02-24 Boehringer Ingelheim Animal Health USA Inc. Attenuated Bordetella Bronchiseptica Strains, Oral Vaccines Containing the Attenuated Strains, and Methods of Making & Use Thereof
AU2021325149A1 (en) 2020-08-14 2023-03-02 ILiAD Biotechnologies, Inc. Lyophilized live bordetella vaccines
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases
EP4247397A4 (en) * 2020-11-17 2024-11-06 Iliad Biotechnologies, LLC TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES
CN113429188B (zh) * 2021-06-18 2022-06-10 湖北沛高环保科技有限公司 一种尾矿固废综合处理利用方法
CN116265584A (zh) * 2021-12-17 2023-06-20 远大赛威信生命科学(南京)有限公司 百日咳抗原重组表达载体及其工程菌和应用
WO2025257397A1 (en) * 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
CN118853525B (zh) * 2024-09-26 2025-01-07 上海羽冠生物技术有限公司 经修饰的百日咳鲍特菌菌株

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) * 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
US9119804B2 (en) 2006-03-10 2015-09-01 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
CA2669485C (en) 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
WO2008156753A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma Early intervention of viral infections with immune activators
JP2011116659A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
SG175803A1 (en) 2009-04-28 2011-12-29 Pasteur Institut Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
DK2773371T3 (da) 2011-11-02 2020-03-09 Nat Univ Singapore Virkning af en svækket bordetella-stamme mod allergisk sygdom
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains

Also Published As

Publication number Publication date
JP2015536134A (ja) 2015-12-21
JP6914976B2 (ja) 2021-08-04
AU2013333928B2 (en) 2017-11-30
CN104936976A (zh) 2015-09-23
AU2013333928A1 (en) 2015-04-09
HK1213926A1 (en) 2016-07-15
SG10201706392YA (en) 2017-09-28
JP2019088303A (ja) 2019-06-13
EP2909229A1 (en) 2015-08-26
ES2715651T3 (es) 2019-06-05
US9528086B2 (en) 2016-12-27
CN104936976B (zh) 2019-11-22
EP3459966B1 (en) 2019-11-27
CA2887055A1 (en) 2014-04-24
JP2021164481A (ja) 2021-10-14
DK3459966T3 (da) 2020-02-17
EP2909229B1 (en) 2018-12-12
SG11201502010TA (en) 2015-04-29
EP3459966A1 (en) 2019-03-27
JP7277516B2 (ja) 2023-05-19
WO2014060514A1 (en) 2014-04-24
JP6473086B2 (ja) 2019-02-20
ES2771675T3 (es) 2020-07-06
US20150210978A1 (en) 2015-07-30
CN110923181A (zh) 2020-03-27
EP2722338A1 (en) 2014-04-23
DK2909229T3 (en) 2019-03-25

Similar Documents

Publication Publication Date Title
CA2887055C (en) A bordetella pertussis strain encoding a hybrid fha protein for increased immunogenicity and lacking a native fha protein
Locht et al. The filamentous haemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp.
DK1994139T3 (en) Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
CN1909924B (zh) 含有细菌鞭毛蛋白作为活性成分的粘膜疫苗佐剂
Renauld-Mongenie et al. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.
CN113769076A (zh) 抗猪链球菌感染的疫苗组合物
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Marzouqi et al. Development of improved vaccines against whooping cough: current status
Wei et al. Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99
JP2023503058A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Ho et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates
Olivera et al. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection
Li et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e
Reveneau et al. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis
JP6401148B2 (ja) 抗原および抗原の組み合わせ
HK40003310A (en) Novel recombinant bordetella strains
HK40003310B (en) Novel recombinant bordetella strains
HK1213926B (en) Novel recombinant bordetella strains
US20150238590A1 (en) Use of the salmonella spp type iii secretion proteins as a protective vaccination
CN101400783B9 (zh) 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗
Guzmàn et al. Use of Salmonella Spp. Carrier Strains to Deliver Bordetella Pertussis Antigens in Mice using the oral Route
Locht et al. Bordetella pertussis Highly Attenuated
Olivera et al. Research Article Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects against Bordetella pertussis Infection
Hauser et al. Site-specific Alterations in the B Oligomer that Affect Receptor-binding Activities and Mitogenicity of Permssis Toxin By Yves Lobet, Christiane Feron, Guy Dequesne, Etienne Sirnoen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180829